2024-10-13 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and markets a wide range of healthcare products.

**Performance Analysis:**

1. **Relative Performance:**
    - ABBV's cumulative return of 152.4% outperforms the S&P 500 (VOO) with a cumulative return of 135.82%. 
    - The current outperformance is 16.58%, placing it at 58.07% relative to the historical range of performance differences.
    
2. **Recent Price Movements:**
    - Closing Price: 194.19
    - 5-Day Moving Average: 193.87
    - 20-Day Moving Average: 194.26
    - 60-Day Moving Average: 191.73
    
3. **Technical Indicators:**
    - RSI (Relative Strength Index): 51.02, indicating neutral market sentiment.
    - PPO (Percentage Price Oscillator): -0.14, suggesting potential for a downward correction.
    - Delta_Previous_Relative_Divergence: -6.63, indicating short-term bearish momentum.
    - Expected Return: 1.658710617083333%, representing an estimated 5-year return above the S&P 500.
    
4. **Recent Earnings and Outlook:**
    - AbbVie's latest earnings report (2024-07-25) showed an EPS of 2.65, exceeding the analysts' expectation of 2.57. This positive earnings surprise suggests that the company's revenue and profitability remain strong.
    - However, with upcoming patent expirations for key drugs,  future earnings growth might face headwinds.

5. **News and Recent Issues:**
    - **Recent Market Outlook:**  ABBV is facing growing competition in the biopharmaceutical market, particularly for its key products like Humira.  The company's growth strategy is based on new drug development, pipeline expansion, and strategic acquisitions.
    - **Analyst Opinions:** Many analysts are optimistic about ABBV's long-term growth potential, highlighting its strong brand, diverse product portfolio, and commitment to research and development.
    - **Performance Highlights:** AbbVie has consistently delivered strong financial performance and dividend growth. However, the stock price may be affected by market volatility and uncertainty surrounding future drug approvals. 

**Overall Analysis:**

ABBV currently outperforms the S&P 500, showing strong earnings performance and a positive outlook for long-term growth. However, technical indicators point to potential near-term weakness, and upcoming patent expirations might pose challenges for the company. Investors should monitor future earnings releases and regulatory updates for further insight into AbbVie's performance. 
